Business
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data f
About this update from Imunon, Inc.
[{"type":"image","alt":"Imunon, Inc.","displaySize":"","headline":null,"caption":"Imunon, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pOVE3xhQvQP6wH..j_xlsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62","width":290,"height":91}},"lazy":false},{"type":"text","content":"Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented ","length":123,"tagName":"p"},{"type":"text","content":"Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA","length":113,"tagName":"p"},{"type":"text","content":"LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is being held May 30 - June 3, 2025, in Chicago, Illinois and virtually. IMUNON recently announced alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation.","length":759,"tagName":"p"},{"type":"text","content":"IMNN-001, based on the company’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (St...